Qiagen’s NeuMoDx Multiplex Test Receives the US FDA’s EUA and Expands its COVID-19 Portfolio

 Qiagen’s NeuMoDx Multiplex Test Receives the US FDA’s EUA and Expands its COVID-19 Portfolio

Qiagen’s NeuMoDx Multiplex Test Receives the US FDA’s EUA and Expands its COVID-19 Portfolio

Shots:

  • The US FDA has granted EUA for Qiagen’s NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help in identifying and differentiate individuals suspected of respiratory viral infection consistent with COVID-19
  • Qiagen launched the multiplex test in the EU in Nov’2020 and will now begin commercialization in the US. The company acquired NeuMoDx in Sept’2020 and the launch of this test strengthens QIAgen’s footprint in PCR and expand its COVID-19 portfolio
  • The 4-plex test utilizes the high-throughput, automated testing capabilities of the NeuMoDx systems, which includes an assay menu for respiratory, blood-borne virus, transplant, and reproductive health disease areas

Click here ­to­ read full press release/ article | Ref: Qiagen | Image: Qiagen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post